PPARG and cardiac hypertrophy: Tan et al. previously identified groups of genes associated with antidiabetic (blood glucose correction) and adverse effects (cardiac hypertrophy) in rodents and described a selectivity index that quantitates whether a PPARγ-binding ligand has relatively greater antidiabetic or adverse effects (Tan et al., 2012).